Investing.com – Incyte NASDAQ: reported Tuesday the results of their first quarter. They beat analyst forecasts, and had revenue that was lower than expected.

Incyte reported earnings per share at $0.55 on revenues of $733.24M. Investing.com polled analyst to predict EPS of $0.458 based on $750.25M in revenue.

Incyte shares rose 39.27% over the first of the year. However, they are down 13.83% from their 52 week high $88.26 on June 28, 2021. They are outperforming the S&P 500 which is down 12.82% from the start of the year.

Incyte shares were down 3.84% after the report.

Incyte’s earnings in the Healthcare sector are following closely this month

Incyte reports on UnitedHealth’s earnings beat on April 14. UnitedHealth reported EPS at $5.49 for revenue $80.15B. Forecasts were for EPS of $5.36 and revenue $78.73B.

J&J had beat expectations on April 19 with first quarter EPS of $2.67 on revenue of $23.43B, compared to forecast for EPS of $2.59 on revenue of $23.62B.

Keep up to date with all the earnings reports coming soon by visiting Investing.com’s earnings calendar